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AbstrAct
Objective Two randomised controlled trials, AMBITION 
(NCT00109408) and ADACTA (NCT01119859), showed 
tocilizumab (TCZ) monotherapy superior to methotrexate 
(MTX) and adalimumab (ADA) monotherapy, respectively, 
for improving rheumatoid arthritis (RA) disease activity. 
This study compared the benefit of TCZ versus MTX or ADA 
monotherapy for improving patient-reported outcomes 
(PROs) in patients with RA.
Methods PROs included patient global assessment (PtGA), 
pain, Health Assessment Questionnaire Disability Index 
(HAQ-DI), Functional Assessment of Chronic Illness Therapy 
(FACIT)-Fatigue and Short Form-36 (SF-36) physical 
component summary (PCS) and mental component 
summary (MCS) and eight domain scores. Outcomes 
included proportions of patients reporting changes from 
baseline in PRO scores ≥minimum clinically important 
differences (MCID) and ≥age-matched and gender-
matched normative values at 24 weeks.
Results In AMBITION, TCZ-treated patients reported 
significantly greater mean improvements in HAQ (−0.7 
vs −0.5), FACIT-Fatigue (8.7 vs 5.7), SF-36 PCS (9.8 
vs 7.8) and five SF-36 domains at week 24 than with 
MTX; 45.0%–84.0% of TCZ-treated patients reported 
improvements ≥MCID, and 24.3%–52.1% reported 
scores ≥normative values across all PROs versus 39.4%–
81.8% and 14.5%–45.0%, respectively, with MTX. In 
ADACTA, TCZ-treated patients reported significantly greater 
improvements in PtGA (−42.3 vs −31.8), pain (−40.1 vs 
−28.7), SF-36 MCS (7.9 vs 5.0) and three SF-36 domains 
than with ADA; 57.7%–83.3% of TCZ-treated patients 
reported improvements ≥MCID, and 22.1%–49.3% 
reported scores ≥normative values across all PROs versus 
13.6%–37.8%, respectively, with ADA.
Conclusions TCZ monotherapy resulted in more patients 
reporting clinically meaningful PRO improvements and 
PRO scores ≥normative values compared with MTX or ADA 
monotherapy.
Trial registration numbers NCT00109408 and 
NCT01119859; Post-results.
ORIGINAl ARTICle
Impact of tocilizumab monotherapy on 
patient-reported outcomes in patients 
with rheumatoid arthritis from two 
randomised controlled trials
Vibeke Strand,1 Margaret Michalska,2 Christine Birchwood,2 
Jinglan Pei,2 Katie Tuckwell,3 Rebecca Finch,9 Cem Gabay,10 Arthur Kavanaugh,11 
Graeme Jones12
To cite: Strand V, Michalska M, 
Birchwood C, et al. Impact of 
tocilizumab monotherapy on 
patient-reported outcomes 
in patients with rheumatoid 
arthritis from two randomised 
controlled trials. RMD Open 
2017;3:e000496. doi:10.1136/
rmdopen-2017-000496
 ► Prepublication history and 
additional material for this paper 
are available online. To view 
please visit the journal (http:// dx. 
doi. org/ 10. 1136/ rmdopen- 2017- 
000496).
Received 12 May 2017
Revised 7 August 2017
Accepted 11 August 2017
For numbered affiliations see 
end of article.
Correspondence to
Professor Graeme Jones;  
 graeme. jones@ utas. edu. au
Rheumatoid arthritis
Key messages
What is already known about this subject?
 ► Tocilizumab (TCZ) monotherapy was shown 
superior to methotrexate (MTX) monotherapy 
and adalimumab (ADA) monotherapy in two 
randomised, controlled trials (AMBITION and 
ADACTA, respectively) for improving disease activity 
in patients with active rheumatoid arthritis (RA); 
however, there are limited data regarding the 
impact of TCZ monotherapy on patient-reported 
outcomes (PROs).
What does this study add?
 ► In this post hoc analysis of the AMBITION and 
ADACTA trial populations, treatment with TCZ, MTX 
or ADA as monotherapy resulted in substantial 
and clinically meaningful improvements in PROs, 
including patient global assessment, pain, Health 
Assessment Questionnaire Disability Index, 
Functional Assessment of Chronic Illness Therapy-
Fatigue and Short Form-36 physical and mental 
component summary and eight domain scores, over 
24 weeks.
 ► TCZ monotherapy resulted in greater mean 
improvements from baseline in PRO scores and 
more patients reporting clinically meaningful PRO 
improvements and PRO scores ≥ age-matched and 
gender-matched normative values compared with 
MTX or ADA monotherapy.
How might this impact on clinical practice?
 ► Treatment with TCZ, MTX or ADA monotherapy was 
effective in improving PROs, including health-
related quality of life, in patients with active RA; 
however, TCZ monotherapy was more effective 
overall compared with MTX or ADA monotherapy.
 ► Results of these trials indicate that it is now 
possible for patients with RA to achieve PRO scores 
that more closely approach those reported by 
healthy populations.
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InTROduCTIOn
Rheumatoid arthritis (RA) is a systemic autoimmune 
disorder characterised by inflammation of the joints. 
Patients with RA often experience diminished health-re-
lated quality of life (HRQOL) with respect to both phys-
ical functioning and emotional state due to the pain, stiff-
ness, fatigue and disability that can result from this inflam-
mation.1–4 The goal of treatment in patients with RA is to 
reduce disease activity and improve patients’ HRQOL. 
Patient-reported outcomes (PROs) are important meas-
ures when determining response to therapy in patients 
with RA, and patients report that, from their perspective, 
these measures of HRQOL are more important than 
traditional measures of clinical disease activity.5–9
Methotrexate (MTX) is the recommended first-line 
treatment for patients with RA.10 For patients with inad-
equate responses to MTX, addition of biological therapy 
in conjunction with MTX is recommended.10 However, 
approximately one-third of patients with RA who receive 
biologics do so as monotherapy, most often due to intoler-
ance of or contraindications to MTX or by patient choice 
to reduce personal medication burden without physician 
consultation.11 12 It is therefore necessary to evaluate the 
efficacy of biological monotherapy for improvement of 
both clinical disease activity and PROs in patients with 
RA.
Tocilizumab (TCZ) is a monoclonal antibody that 
inhibits the interleukin-6 receptor and is approved for the 
treatment of patients with moderate to severe RA. Previous 
randomised controlled trials (RCTs) have demonstrated 
the efficacy of TCZ, both as monotherapy and in combi-
nation with conventional synthetic disease-modifying 
antirheumatic drugs, such as MTX, for improvement of 
disease activity in patients with RA.13 14 In addition, in 
two RCTs, AMBITION and ADACTA, respectively, TCZ 
monotherapy was shown superior to MTX monotherapy 
and monotherapy with the tumour necrosis factor inhib-
itor (TNFi) adalimumab (ADA).15 16
In a phase 3 RCT, TCZ with concomitant MTX was 
shown to significantly improve PROs over 24 weeks 
compared with placebo in patients with RA who were 
inadequate responders to TNFis.17 However, there are 
limited data regarding the impact of TCZ monotherapy 
on PROs. The objective of this study was to compare 
the efficacy of TCZ monotherapy with that of MTX or 
ADA monotherapy for improvement in PROs in patients 
with RA based on post hoc analyses of AMBITION 
(NCT00109408) and ADACTA (NCT01119859).15 16
MeTHOds
study design and patient population
The study designs and patient inclusion and exclusion 
criteria for both RCTs have been previously described 
and are summarised in online supplementary table S1. 
Briefly, AMBITION was a phase 3 multicentre RCT that 
compared the efficacy of TCZ monotherapy with that of 
MTX monotherapy in patients with moderate to severely 
active RA.16 Eligible patients were MTX naïve or had 
discontinued MTX ≥6 months prior to randomisation 
and were not inadequate responders to MTX (MTX-
IR) or TNFis. Study participants received TCZ 8 mg/
kg intravenous every 4 weeks as monotherapy or MTX 
7.5–20 mg/week as monotherapy.
ADACTA was a phase 4 multicentre RCT that 
compared the efficacy of TCZ monotherapy with that of 
ADA monotherapy in patients with RA.15 Patients had 
severe active RA, were biologic naïve and MTX-IR or 
otherwise inappropriate candidates for continued MTX 
treatment by judgement of the investigator. Study partic-
ipants received TCZ 8 mg/kg intravenous every 4 weeks 
or ADA 40 mg subcutaneous (SC) every 2 weeks. At week 
16, or any time thereafter, patients in both treatment 
arms with <20% improvement in swollen and tender joint 
counts were eligible for escape treatment with weekly SC 
injections (ADA and placebo).
Patient-reported outcomes
HRQOL was assessed at baseline and 24 weeks in each 
study population. PROs assessed included patient 
global assessment (PtGA; visual analogue scale (VAS), 
0–100 mm); pain (VAS, 0–100 mm); Health Assessment 
Questionnaire Disability Index (HAQ-DI; 0–3); Func-
tional Assessment of Chronic Illness Therapy (FACIT)-Fa-
tigue (0–52); Short Form-36 (SF-36) physical compo-
nent summary (PCS) and mental component summary 
(MCS) scores (mean: 50, SD: 10); and eight domains 
(physical functioning, role-physical, bodily pain, general 
health, vitality, social functioning, role-emotional and 
mental health; scored 0–100). Study outcomes included 
mean changes from baseline in PROs, the proportion 
of patients who reported improvements from base-
line ≥minimum clinically important differences (MCID) 
for each PRO18 19 and the proportion of patients who 
reported scores ≥age-matched and gender-matched 
normative values (table 1).18–20 Mean SF-36 domain scores 
were determined at baseline and 24 weeks and compared 
with age-matched and gender-matched normative values 
for each study population using spydergrams.21 Changes 
from baseline in Clinical Disease Activity Index (CDAI) 
were assessed at 24 weeks as a reference for change in 
disease activity.
statistical analysis
Analyses were performed in the primary efficacy patient 
populations in each trial. In AMBITION, the primary 
efficacy hypothesis was to establish non-inferiority of TCZ 
versus MTX in the per-protocol population (TCZ, n=265 
of 286 intention-to-treat (ITT) patients; MTX, n=259 
of 284 ITT patients). In ADACTA, the primary efficacy 
hypothesis was to establish superiority of TCZ versus ADA 
in the ITT population (TCZ, n=163; ADA, n=162). PROs, 
the proportions of patients reporting improvements 
≥ MCID from baseline to week 24 and those reporting 
scores ≥ age-matched and gender-matched normative 
values at week 24 were compared between TCZ and MTX 
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Table 1 PRO age-matched and gender-matched 
normative values in non-RA population without comorbid 
conditions
AMBITION ADACTA
HAQ-DI, 0–3 <0.5 <0.5
FACIT-Fatigue, 0–52 ≥40 ≥40
SF-36 PCS (mean:50, SD: 10) ≥50 ≥50
SF-36 MCS (mean: 50, SD:10) ≥50 ≥50
SF-36 domains, 0–100
  Physical functioning ≥78.8 ≥78.3
  Role-physical ≥79.1 ≥79.0
  Bodily pain ≥67.4 ≥68.1
  General health ≥68.2 ≥69.3
  Vitality ≥56.6 ≥58.3
  Social functioning ≥81.7 ≥83.4
  Role-emotional ≥85.0 ≥86.3
  Mental health ≥72.9 ≥75.1
FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, 
Health Assessment Questionnaire Disability Index; MCS, mental 
component summary; PCS, physical component summary; PRO, 
patient-reported outcome; RA, rheumatoid arthritis; SF-36, Short 
Form-36.
or ADA in AMBITION and ADACTA, respectively. For 
patients in ADACTA who received escape therapy and 
completed the study to 24 weeks (TCZ, n=7; ADA, n=8), 
results were carried forward from the time of escape. In 
AMBITION, p values were not reported, as non-inferiority 
was determined from the lower limit of the 95% CI for 
the treatment difference (TCZ minus MTX); if the lower 
limit of the 95% CI for the treatment difference was >0, 
then superiority was achieved. In ADACTA, p values were 
reported to determine statistically significant differences 
between TCZ and ADA.
Continuous endpoints were compared using least 
squares mean changes from baseline calculated using 
an analysis of covariance. The proportion of patients 
reporting improvements from baseline ≥MCID at 24 
weeks was analysed for each PRO and SF-36 domain 
using a Cochran-Mantel-Haenszel χ2 test. All analyses 
were adjusted for site (AMBITION)/region (ADACTA), 
baseline scores (ADACTA) and duration of RA.
ResulTs
Baseline patient characteristics
Patient demographics and baseline disease character-
istics have been previously described, were generally 
comparable between treatment groups within each RCT 
and showed that patients were substantially impacted by 
their disease (table 2).15 16 In the MTX and TCZ arms 
in AMBITION, 81% and 83% of patients were women, 
73% and 71% white, mean age was 50.1 and 51.1 years 
and mean disease duration 6.3 and 6.4 years, respectively; 
mean baseline CDAI was 43.2 in both arms. In the ADA 
and TCZ arms in ADACTA, 82% and 79% of patients 
were women, 82% and 89% white, mean age was 53.3 and 
54.4 years, mean disease duration 6.3 and 7.3 years and 
mean baseline CDAI 43.1 and 40.8, respectively.
Improvement in PROs at 24 weeks
Patients who received TCZ monotherapy in both RCTs 
reported greater improvements from baseline across 
all PROs at 24 weeks than those who received MTX or 
ADA monotherapy. In AMBITION, TCZ-treated patients 
reported significantly greater improvements from base-
line in HAQ-DI, FACIT-Fatigue and SF-36 PCS scores at 
24 weeks than MTX-treated patients (table 3). In addi-
tion, TCZ-treated patients reported significantly greater 
improvements from baseline in five of eight SF-36 domains 
(physical functioning, bodily pain, vitality, social func-
tioning and mental health) than MTX-treated patients. 
In ADACTA, patients who received TCZ reported signifi-
cantly greater improvements from baseline in PtGA, pain 
and SF-36 MCS scores at 24 weeks than those who received 
ADA (table 3). TCZ-treated patients also reported signif-
icantly greater improvements from baseline in three of 
eight SF-36 domains (role-physical, vitality and social 
functioning) than ADA-treated patients.
Patients who received TCZ monotherapy in both RCTs 
reported higher mean scores across all SF-36 domains, 
which more closely approached age-matched and gender-
matched normative values, at 24 weeks than patients who 
received MTX or ADA monotherapy (figure 1), indicative 
of clinically meaningful improvements. Consistent with 
reported improvements in PROs, patients treated with 
TCZ monotherapy in either RCT experienced signifi-
cantly greater improvements from baseline in CDAI at 
24 weeks than patients who received MTX or ADA mono-
therapy (table 3).
Patients reporting improvements ≥MCId at 24 weeks
At least one patient in all treatment groups reported 
improvements ≥MCID across all PROs. In AMBITION, 
significantly more patients who received TCZ mono-
therapy reported improvements from baseline ≥MCID 
in HAQ-DI (number needed to treat (NNT): 11.0), 
FACIT-Fatigue (NNT: 7.8), SF-36 role-physical (NNT: 
10.9) and vitality (NNT: 14.5) domains at 24 weeks than 
patients who received MTX monotherapy (figure 2A; 
online supplementary table S2). In ADACTA, a signifi-
cantly higher proportion of patients who received TCZ 
monotherapy reported clinically meaningful improve-
ments from baseline in pain (NNT: 7.5), SF-36 MCS 
(NNT: 6.4) and SF-36 vitality domain (NNT: 6.0) scores 
at 24 weeks compared with patients who received ADA 
monotherapy (figure 2B; online supplementary table 
S2).
Patients reporting scores ≥age-matched and gender-matched 
normative values at 24 weeks
The proportions of patients reporting scores ≥age-matched 
and gender-matched normative values at baseline were 
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Table 2 Baseline demographics, disease characteristics and PRO scores of patients in AMBITION and ADACTA
AMBITION ADACTA
Baseline characteristic* TCZ 8 mg/kg (n=265) MTX 7.5–20 mg (n=259) TCZ 8 mg/kg (n=163) ADA 40 mg (n=162)
Age, years 51.1 (13.1) 50.1 (12.8) 54.4 (13.0) 53.3 (12.4)
Female, n (%) 219 (83) 211 (81) 129 (79) 133 (82)
White, n (%) 187 (71) 188 (73) 145 (89) 133 (82)
Disease duration, years 6.4 (7.7) 6.3 (7.9) 7.3 (8.1) 6.3 (6.9)
Number of prior DMARDs 1.2 (1.3) 1.1 (1.4) 2.0 (1.1) 2.0 (1.1)
CDAI 43.2 (12.9) 43.2 (11.8) 40.8 (12.3) 43.1 (12.6)
PtGA, VAS 0–100 mm 64.0 (21.5) 65.4 (19.5) 71.2 (20.8) 73.4 (19.4)
Pain, VAS 0–100 mm 59.2 (22.5) 61.3 (20.4) 67.2 (21.3) 67.9 (20.7)
HAQ-DI, 0–3 1.6 (0.7) 1.5 (0.6) 1.6 (0.6) 1.7 (0.6)
FACIT-Fatigue, 0–52 27.4 (10.6) 27.8 (10.5) 24.9 (10.6) 24.1 (11.2)
SF-36 PCS (mean: 50, SD: 10) 31.9 (7.5) 31.1 (6.9) 30.5 (7.9) 30.2 (7.9)
SF-36 MCS (mean: 50, SD: 10) 40.2 (12.0) 40.6 (11.3) 39.7 (12.0) 38.9 (12.3)
SF-36 domains, 0–100
  Physical functioning 37.1 (24.1) 37.0 (23.2) 34.4 (22.0) 32.9 (24.0)
  Role-physical 13.6 (26.8) 13.3 (28.2) 34.0 (20.9) 35.4 (24.2)
  Bodily pain 29.1 (17.2) 27.6 (15.2) 27.2 (19.1) 24.5 (16.7)
  General health 42.1 (19.9) 40.1 (19.6) 42.5 (19.4) 40.6 (18.6)
  Vitality 35.7 (19.7) 37.0 (19.1) 32.7 (18.1) 32.8 (19.5)
  Social functioning 48.3 (26.4) 50.2 (24.8) 48.0 (26.9) 47.7 (26.8)
  Role-emotional 34.9 (41.7) 32.7 (42.8) 54.4 (30.7) 50.3 (31.7)
  Mental health 55.5 (22.0) 57.7 (20.3) 54.9 (19.5) 54.1 (20.9)
*All values are presented as mean (SD) unless otherwise indicated.
ADA, adalimumab; CDAI, Clinical Disease Activity Index; DMARDs, disease-modifying antirheumatic drugs; FACIT, Functional Assessment of 
Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire Disability Index; MCS, mental component summary; MTX, methotrexate; 
PCS, physical component summary; PRO, patient-reported outcome; PtGA, patient global assessment; SF-36, Short Form-36; 
TCZ, tocilizumab; VAS, visual analogue scale.
comparable between treatment groups in both RCTs. In 
AMBITION, the proportion of patients with normative 
scores at baseline ranged from 0.8% and 1.5% (SF-36 PCS; 
MTX and TCZ, respectively) to 23.6% and 24.2% (SF-36 
MCS; TCZ and MTX, respectively), with a similar range 
across SF-36 domains: 1.2% and 3.4% (bodily pain; MTX 
and TCZ, respectively) to 24.4% and 25.3% (role-emotional; 
TCZ and MTX, respectively). In ADACTA, the proportion 
of patients with normative scores at baseline ranged from 
1.9% and 2.5% (SF-36 PCS; TCZ and ADA, respectively) to 
20.8% and 21.1% (SF-36 MCS; ADA and TCZ, respectively), 
with a similar range across SF-36 domains: 1.2% (role-phys-
ical; TCZ) and 2.5% (bodily pain; ADA) to 17.4% and 19.1% 
(role-emotional; TCZ and ADA, respectively).
The proportion of patients reporting scores 
≥age-matched and gender-matched normative values at 
24 weeks was greater than at baseline for all treatment 
groups across all PROs and indicated clinically important 
improvements in TCZ-treated patients (figure 3). In 
AMBITION, 24%–44% of TCZ-treated patients reported 
scores ≥normative values across HAQ-DI, FACIT-Fatigue 
and SF-36 PCS/MCS and 30%–52% across SF-36 domains 
at week 24 compared with 15%–42% and 21%–41% 
of MTX-treated patients, respectively. In ADACTA, 
the proportion of TCZ-treated patients reporting 
scores ≥normative values ranged from 22% to 49% for 
HAQ-DI, FACIT-Fatigue and SF-36 PCS/MCS and 23% 
to 41% across SF-36 domains at week 24 compared 
with 14%–38% and 18%–33% of ADA-treated patients, 
respectively.
dIsCussIOn
Consistent with CDAI responses in AMBITION and 
ADACTA, TCZ monotherapy was more effective 
improving PROs in patients with active RA than either 
MTX or ADA monotherapy. Although patients treated 
with MTX or ADA reported clinically meaningful 
improvement in PROs, patients who received TCZ 
reported significantly greater improvements from base-
line at 24 weeks than patients who received either MTX 
or ADA. Similarly, a higher proportion of TCZ-treated 
patients reported improvements from baseline ≥MCID as 
well as scores ≥age-matched and gender-matched norma-
tive values, indicative of clinically meaningful changes, at 
24 weeks than patients treated with either MTX or ADA.
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Table 3 LSM changes from baseline in PROs at 24 weeks in AMBITION and ADACTA
AMBITION* ADACTA*
LSM change from 
baseline†
LSM change from 
baseline†
TCZ MTX Difference (95% CI) TCZ ADA Difference (95% CI) p value
PtGA,
VAS 0–100 mm
−33.5 −29.5 −4.1 (−9.3 to 1.2) −42.3 −31.8 −10.5 (−17.7 to −3.3) 0.004
Patient pain,
VAS 0–100 mm
−31.5 −29.5 −2.0 (−7.1 to 3.1) −40.1 −28.7 −11.3 (−18.3 to −4.3) 0.002
HAQ-DI, 0–3 −0.7‡ −0.5 −0.2 (−0.3 to −0.1) −0.7 −0.5 −0.2 (−0.3 to 0.0) 0.065
FACIT-Fatigue, 0–52 8.7‡ 5.7 2.9 (1.0 to 4.8) 11.4 8.9 2.5 (−0.3 to 5.3) 0.077
SF-36 PCS (mean: 50, SD: 
10)
9.8‡ 7.8 2.0 (0.4 to 3.7) 9.2 7.6 1.6 (−0.6 to 3.8) 0.164
SF-36 MCS (mean: 50, SD: 
10)
6.8 4.8 2.0 (−0.3 to 4.2) 7.9 5.0 2.9 (0.0 to 5.9) 0.050
SF-36 domains,
0–100
Physical functioning 23.0‡ 16.5 6.5 (2.2 to 10.8) 20.0 16.0 4.0 (−1.5 to 9.5) 0.156
Role-physical 37.3 29.8 7.5 (−0.1 to 15.2) 23.8 16.4 7.4 (1.3 to 13.5) 0.017
Bodily pain 30.4‡ 24.8 5.7 (1.9 to 9.5) 29.3 23.8 5.5 (−0.2 to 11.2) 0.058
General health 12.7 9.6 3.1 (−0.1 to 6.3) 10.7 7.6 3.0 (−1.2 to 7.3) 0.156
Vitality 19.5‡ 12.9 6.6 (2.9 to 10.4) 19.1 14.0 5.1 (0.2 to 9.9) 0.040
Social functioning 21.5‡ 16.4 5.1 (1.0 to 9.3) 23.4 17.1 6.3 (0.6 to 12.0) 0.032
Role-emotional 28.5 22.2 6.3 (−1.5 to 14.1) 15.4 9.7 5.7 (−0.6 to 12.0) 0.077
Mental health 14.3‡ 10.2 4.1 (0.8 to 7.5) 13.5 9.3 4.2 (−0.1 to 8.5) 0.057
CDAI −25.6§ −19.8 −5.8 (−8.6 to −3.0) −23.8 −18.9 −4.9 (−8.3 to −1.5) 0.005
*Analyses were performed using the per-protocol population in AMBITION (TCZ, n=265; MTX, n=259) and the intention-to-treat population in 
ADACTA (TCZ, n=163; ADA, n=162).
†Adjusted for site (AMBITION)/region (ADACTA), baseline score (ADACTA) and duration of RA.
‡Statistical significance is demonstrated by the lower limit of the 95% CI of TCZ – MTX >0.
§Statistical significance is demonstrated by the upper limit of the 95% CI of TCZ – MTX <0.
ADA, adalimumab; CDAI, Clinical Disease Activity Index; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health 
Assessment Questionnaire Disability Index; LSM, least squares mean; MCS, mental component summary; MTX, methotrexate; PCS, physical 
component summary; PRO, patient-reported outcome; PtGA, patient global assessment; RA, rheumatoid arthritis; SF-36, Short Form-36; 
TCZ, tocilizumab; VAS, visual analogue scale.
Patients in both RCT populations were substan-
tially impacted by their disease at baseline, indicated 
by mean PRO scores below normative values in both 
trials and <25% of patients in AMBITION and <20% 
of patients in ADACTA reporting scores ≥normative 
values in any PRO. The greater proportions of patients 
reporting normative scores at baseline in AMBITION 
versus ADACTA likely reflect a greater impact of disease 
in the biologic-eligible (ADACTA) versus an MTX-naïve 
(AMBITION) population. Treatment with TCZ, MTX 
or ADA monotherapy resulted in clinically meaningful 
improvements across all PROs. Although NNTs are typi-
cally generated in comparison with placebo treatment, 
NNTs based on HAQ-DI, FACIT and SF-36 physical 
functioning domain score differences in AMBITION 
and pain and SF-36 vitality domain score differences 
in ADACTA, despite active comparisons rather than 
placebo, were clinically meaningful (≤10) favouring 
TCZ monotherapy. Additionally, higher proportions of 
patients in all treatment groups reported scores ≥norma-
tive values at 24 weeks compared with baseline, indic-
ative of clinically important improvements. These data 
indicate that achievement of normative PRO scores that 
more closely match those reported by healthy popula-
tions is an attainable goal for treatment of RA, regardless 
of therapy.
TCZ monotherapy resulted in improvements ≥MCID 
in ≥1 patient across all PROs in both studies, and a 
similar proportion of patients reported scores ≥norma-
tive values at week 24 (AMBITION, 21%–52%; ADACTA, 
22%–49%) despite differences in prior treatment 
experiences between patients enrolled in AMBITION 
versus ADACTA. Thus, TCZ monotherapy was effective 
improving HRQOL in patients with active RA who had 
not experienced failure of MTX or TNFi therapy (AMBI-
TION) and was effective as a first-line biologic in patients 
deemed inappropriate candidates for continued treat-
ment with MTX (ADACTA).
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 1 SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative 
values in the (A) AMBITION and (B) ADACTA trial populations. Analyses were performed using the per-protocol population in 
AMBITION (TCZ, n=265; MTX, n=259) and the intention-to-treat population in ADACTA (TCZ, n=163; ADA, n=162). Normative 
values were defined as age-matched and gender-matched scores in a non-RA population without comorbid conditions. 
AMBITION population: PF: ≥78.8; RP: ≥79.1; BP: ≥67.4; GH: ≥68.2; VT: ≥56.6; SF: ≥81.7; RE: ≥85.0; MH: ≥72.9. ADACTA 
population: PF: ≥78.3; RP: ≥79.0; BP: ≥68.1; GH: ≥69.3; VT: ≥58.3; SF: ≥83.4; RE: ≥86.3; MH: ≥75.1. ADA, adalimumab; BP, 
bodily pain; GH, general health; MH, mental health; MTX, methotrexate; PF, physical functioning; RA, rheumatoid arthritis; RE, 
role-emotional; RP, role-physical; SF, social functioning; SF-36, Short Form-36; TCZ, tocilizumab; VT, vitality.
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Figure 2 Proportion of patients reporting improvement ≥MCID at 24 weeks in the (A) AMBITION and (B) ADACTA trial 
populations. Analyses were performed using the per-protocol population in the AMBITION (TCZ, n=265; MTX, n=259) and the 
intention-to-treat population in ADACTA (TCZ, n=163; ADA, n=162) and adjusted for site (AMBITION)/region (ADACTA), baseline 
score (ADACTA) and duration of RA. The MCID for PROs were defined as follows: HAQ-DI: ≥0.22; PtGA: ≥10; patient pain: ≥10; 
FACIT-Fatigue: ≥4; SF-36 PCS/MCS: ≥2.5; SF-36 domains: ≥5.0. ADA, adalimumab; BP, bodily pain; FACIT, Functional 
Assessment of Chronic Illness Therapy; GH, general health; HAQ-DI, Health Assessment Questionnaire Disability Index; MCS, 
mental component summary; MCID, minimum clinically important differences; MH, mental health; MTX, methotrexate; PCS, 
physical component summary; PF, physical functioning; PROs, patient-reported outcomes; PtGA, patient global assessment; 
RE, role-emotional; RP, role-physical; SF, social functioning; SF-36, Short Form-36; TCZ, tocilizumab; VT, vitality. *p<0.05; 
**p<0.01.
There are few trials examining the impact of TCZ 
monotherapy on PROs in patients with RA, with the 
majority of available data limited to the PROs included in 
the American College of Rheumatology (ACR) core set 
(PtGA, pain and HAQ-DI). With respect to these PROs, 
results observed in AMBITION and ADACTA are consis-
tent with those in the ACT-RAY study, in which biolog-
ic-naïve MTX-IR patients with active RA who switched 
from MTX to TCZ monotherapy reported improve-
ments ≥MCID in PtGA, pain and HAQ-DI at 24 weeks; 
improvements were similar between those who switched 
from MTX to TCZ monotherapy and those who added 
TCZ to MTX.22 However, beyond improvement in the 
ACR core set components, patients have expressed the 
importance of alleviating disruptions to work produc-
tivity, social functioning, fatigue and the negative mental 
and emotional effects resulting from this disease.2 By 
evaluating the impact of TCZ on improvement of fatigue 
and physical, social and mental/emotional well-being 
measures encompassed in the SF-36, the present study 
substantially expands the understanding of the efficacy 
of TCZ improving PROs and patients’ HRQOL.
One limitation of this study is the use of ADA mono-
therapy as the comparator in ADACTA. Although TCZ has 
similar efficacy whether administered as monotherapy or 
with MTX, it is well recognised that ADA in combination 
with MTX is more effective than ADA monotherapy.23 24 
However, for patients who cannot tolerate MTX, the results 
presented here suggest that TCZ monotherapy is more 
effective than ADA monotherapy for improving PROs. 
Another limitation is the evaluation of PROs only up to 
24 weeks; longer studies will be necessary to determine 
the long-term effects of TCZ monotherapy on PROs. An 
inherent limitation to trials evaluating PROs is the potential 
for patient anticipation of improvements due to initiation 
of new therapy, which may influence reporting of results. 
Importantly, reported improvements in PROs correlated 
with significant improvements in CDAI.
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Figure 3 Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 
24 weeks in the (A) AMBITION and (B) ADACTA trial populations. Analyses were performed using the per-protocol population in 
AMBITION (TCZ, n=265; MTX, n=259) and the intention-to-treat population in ADACTA (TCZ, n=163; ADA, n=162). Normative 
values were defined as age-matched and gender-matched scores in a non-RA population without comorbid conditions. 
HAQ-DI: <0.5; FACIT-Fatigue: ≥40; SF-36 PCS/MCS: ≥50; SF-36 domains in the AMBITION population: PF: ≥78.8; RP: ≥79.1; 
BP: ≥67.4; GH: ≥68.2; VT: ≥56.6; SF: ≥81.7; RE: ≥85.0; MH: ≥72.9; SF-36 domains in the ADACTA population: PF: ≥78.3; 
RP: ≥79.0; BP: ≥68.1; GH: ≥69.3; VT: ≥58.3; SF: ≥83.4; RE: ≥86.3; MH: ≥75.1. ADA, adalimumab; BP, bodily pain; FACIT, 
Functional Assessment of Chronic Illness Therapy; GH, general health; HAQ-DI, Health Assessment Questionnaire Disability 
Index; MCS, mental component summary; MH, mental health; MTX, methotrexate; PCS, physical component summary; PF, 
physical functioning; PRO, patient-reported outcome; RA, rheumatoid arthritis; RE, role-emotional; RP, role-physical; SF, social 
functioning; SF-36, Short Form-36; TCZ, tocilizumab; VT, vitality.
COnClusIOns
Treatment with TCZ, MTX or ADA monotherapy was effec-
tive in improving PROs, including HRQOL, in patients 
with active RA. Although patients receiving MTX or ADA 
reported improvements across all PROs, TCZ-treated 
patients reported equivalent or greater improvements. 
Overall, TCZ was more effective over 24 weeks than MTX 
in patients without prior inadequate responses to MTX or 
TNFis and was more effective as a first-line biologic than 
ADA in patients for whom continued treatment with MTX 
was inappropriate. Results of these trials indicate that it is 
now possible for patients with RA to achieve PRO scores that 
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more closely approach those reported by healthy popula-
tions.
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